

REVIEW

Open Access

# HIV restriction in quiescent CD4<sup>+</sup> T cells

Jerome A Zack<sup>1,2,3</sup>, Sohn G Kim<sup>1</sup> and Dimitrios N Vatakis<sup>1\*</sup>

## Abstract

The restriction of the Human Immunodeficiency Virus (HIV) infection in quiescent CD4<sup>+</sup> T cells has been an area of active investigation. Early studies have suggested that this T cell subset is refractory to infection by the virus. Subsequently it was demonstrated that quiescent cells could be infected at low levels; nevertheless these observations supported the earlier assertions of debilitating defects in the viral life cycle. This phenomenon raised hopes that identification of the block in quiescent cells could lead to the development of new therapies against HIV. As limiting levels of raw cellular factors such as nucleotides did not account for the block to infection, a number of groups pursued the identification of cellular proteins whose presence or absence may impact the permissiveness of quiescent T cells to HIV infection. A series of studies in the past few years have identified a number of host factors implicated in the block to infection. In this review, we will present the progress made, other avenues of investigation and the potential impact these studies have in the development of more effective therapies against HIV.

**Keywords:** Quiescent CD4 T cells, HIV infection, Host restriction factors

## Review

### Introduction

Quiescence is a unique feature of our immune system as T lymphocytes can remain at a non-dividing state for prolonged periods of time. The majority of circulating T cells in blood are in a quiescent state. This is characterized by low metabolic rates, low levels of transcription, small size and very long periods of survival [1,2]. It was long thought that T cell quiescence was a default state. A recent series of studies reversed this notion as they demonstrated that a number of transcription factors actively maintained this state [1-10]. To this date, LKLF [3,4,8], FOXO1,3 and 4 [7,11-18], and Tob [6,10,19,20] have been identified as key factors that maintain T cell quiescence. Loss of expression of any of the above proteins resulted in aberrant T cell proliferation, cellular damage due to higher metabolism, and cell death. CD4<sup>+</sup> T cell quiescence and its effect on HIV infection has been a topic of intense investigation as early studies indicated that they are resistant to HIV infection. As a result a strong interest was developed to identify cellular factors that mediate this block and can potentially be the

basis for effective therapeutic approaches against HIV. None of the factors regulating T cell quiescence have been implicated in influencing HIV infection.

In this review, we will discuss the steps of the viral life cycle inhibited in quiescent CD4<sup>+</sup> T cells, the factors involved and the impact these studies have in understanding HIV infection in quiescent T cells as well as the development of better targets against the virus.

### HIV replication is defective in quiescent CD4<sup>+</sup> T cells

For the past two decades, the infection of quiescent CD4 T cells by HIV has been an area of intense investigation. Unlike other retroviruses, HIV replication is not dependent on cell cycle. Nevertheless, HIV and other lentiviruses more efficiently infect non-dividing cells and establish a latent infection [21-23]. While early reports supported the notion that only pre-activated T cells can be infected by HIV [24-26], subsequent studies showed that quiescent T cells could be infected by the virus [27-30]. Yet, key differences arose relating to the degree and levels of infection efficiency.

On the one hand it was shown that HIV viral entry and initiation of reverse transcription were not affected. However, completion of reverse transcription was inefficient resulting in the accumulation of labile, intermediate viral cDNA species [28,29]. Rescue of infection was

\* Correspondence: [dvatakis@ucla.edu](mailto:dvatakis@ucla.edu)

<sup>1</sup>Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA  
Full list of author information is available at the end of the article

possible with stimulation but it was temporally sensitive as production of viral progeny decreased at later reactivation timepoints [29]. Additional work focusing on the CD25<sup>-</sup> (non-activated) and CD25<sup>+</sup> (activated) T cell populations lent more support to the notion that quiescent T cells are resistant to HIV infection [31-33]. In the absence of any stimulation, HIV infection of CD25<sup>-</sup> T cells failed while that of CD25<sup>+</sup> was successful. Furthermore, when total human peripheral blood monocytes were infected, the CD25<sup>-</sup> population did carry viral cDNA suggesting either bystander activation of the non-activated population or more efficient infection via cell-cell contact. Finally, Tang and colleagues further supported the above observations by demonstrating that infection of quiescent cells with HIV did not result in the production of virus [34].

On the other hand, other studies showed that HIV infection of quiescent T cells could be productive. More specifically, they demonstrated that the viral cDNA was fully reverse transcribed and stably localized in the cytosol. This linear cDNA following T cell activation would then integrate and result in the production of viral progeny [27,30]. Thus, the block was not seen at the early stages of infection such as reverse transcription but later either in nuclear transport or integration [27,30]. However, the key conclusion from these studies was that the block could be easily alleviated at any time after infection with T cell activation, a notion not shared by the studies outlined above [29].

Despite the divergent opinions, this early work clearly demonstrated that the life cycle of HIV in quiescent CD4<sup>+</sup> T cells was quite distinct from that of activated T cells and warranted further investigation. As technologies evolved, our knowledge was further expanded in regards to the characteristics of the HIV life cycle in quiescent T cells. Studies by Korin et al utilized a cell cycle progression assay that could assess the levels of both RNA and DNA synthesis and demonstrated that non-dividing T cells can be classified into two categories: (1) cells in the G<sub>0</sub>/G<sub>1a</sub> phase which is characterized by undetectable levels of DNA and RNA synthesis (truly quiescent) and (2) cells in the G<sub>1b</sub> phase which is characterized by high levels of RNA expression but not DNA [35]. Following infection of these two sub-populations of non-dividing T cells, it was shown that cells in the G<sub>1b</sub> stage were susceptible to infection while the truly quiescent G<sub>0</sub>/G<sub>1a</sub> were resistant [35]. Thus, the data did lend a justification for the disagreement raised in the earlier studies. It would have been possible that the rescue seen after stimulation was due to the fact that G<sub>1b</sub> phase cells were infected. More importantly, this study underscored the fact that partly activated but non-dividing T cells can be productively infected by HIV and that quiescent T cells are indeed resistant to infection.

Overall these early studies established that HIV replication in quiescent cells is defective. As new and more sensitive technologies developed, groups were able to further dissect and examine in more detail the stages of the viral life cycle that is impacted in quiescent T cells. These studies were more focused on the events leading up to including integration with a growing number interested in post-integration events.

#### ***Pre-integration blocks to HIV infection in quiescent T cells***

A series of studies using more sensitive PCR techniques further supported the opinion that quiescent T cells were resistant to infection and shed some more light on what stages of the HIV life cycle were impacted. The Siliciano group, using a linker-mediated PCR assay, determined that in quiescent T cells reverse transcription occurred at a slower rate, 2–3 days, and produced viral cDNA with a half life of approximately a day [36]. Despite the formation of full-length viral cDNA, the infection was not productive. In a follow up study, the same group found that the linear non-integrated cDNA was integration competent [37]. Thus, these studies supported and further characterized the presence of labile viral cDNA that was not able to support a productive HIV infection.

Moreover, the development of a sensitive and quantitative assay allowed for the detection of low levels of integration in HIV infected cells [38] and proved to be very useful in the study of HIV infection in quiescent T cells. Using this assay the O'Doherty group demonstrated that quiescent CD4<sup>+</sup> T cells were infectable by HIV resulting in accumulation of viral cDNA over a three-day period and subsequent integration [39-41]. Furthermore, the authors were able to induce expression of virus following stimulation with IL-7 and anti-CD3/anti-CD28. These studies demonstrated that a productive and latent infection could be established in quiescent cells. However, despite these promising results, the major deficiencies previously seen in quiescent T cells, still persisted and potentially were masked by the use of spinoculation [42] as a method of infection.

Studies done by our group using quantitative real time PCR assays and the integration assay developed by the O'Doherty group analyzed in more detail the kinetics of HIV infection in quiescent CD4 T cells and compared them with that of stimulated T cells [43]. Based on our results, we did not observe any defects on viral entry. However, we did see a significant difference in reverse transcription. Unlike the earlier studies, initiation of reverse transcription was severely decreased (30-fold lower) in quiescent T cells. Interestingly, there was completion of reverse transcription that was delayed by 16 - hours. The newly synthesized viral cDNA did integrate in quiescent cells with efficiency similar to that of

activated T cells. However, the process was completed 24 hours later than that seen in activated T cells. The integrated provirus found in quiescent T cells did express low levels of multiply spliced viral mRNA, however this did not translate into the expression of detectable viral protein. Interestingly, activation immediately after infection did not rescue this inefficient infection process in quiescent T cells [43]. The results from our studies revealed and pointed to debilitating blocks in the early stages of the viral life cycle as well as delays leading up to viral integration.

#### ***HIV integration and viral expression defects in quiescent T cells***

The finding that there is proviral DNA in quiescent T cells raised the possibility that quiescent T cells can be a reservoir that could support a spreading infection. Integrated virus was previously found in resting cells of HIV infected patients but this was attributed to the infection of previously activated T cells that returned to a resting state [44]. Furthermore, the presence viral mRNA in our studies but the lack of detectable viral protein [43] raised the possibility that HIV integration site selection in quiescent T cells may be distinct from activated ones. Since T cell quiescence is an actively maintained state and HIV preferentially integrates into transcriptionally active units, it would be inferred that a distinct distribution of integration sites could explain our observations. Others and we examined integration site selection in quiescent CD4<sup>+</sup> T cells [45,46]. Based on our data, integration in both activated and quiescent CD4<sup>+</sup> T cells occurred in transcriptionally active units such as housekeeping genes that were not affected by cell state [45]. The orientation of integrants between the two cell types was similar as well as the chromosomal locations. Yet, despite the observed similarities, proviral DNA in quiescent cells exhibited higher levels of abnormal LTR-host junctions [45]. Furthermore, we observed higher levels of 2-LTR circles with both normal and abnormal junctions [45]. These patterns suggest that the delays prior to integration had a severe detrimental effect on the ends of the viral cDNA. On the other hand, in the studies by Brady et.al, HIV integration patterns were somewhat different between stimulated and quiescent T cells [46]. HIV integrated in less transcriptionally active regions in quiescent cells when compared to stimulated cells, but the observed differences were modest. Yet, despite the differing conclusions, both studies identified additional potential blocks to HIV infection: (i) LTR attrition that can lead to the integration of defective virions and (ii) integration into transcriptionally repressed regions.

The integration site analysis outlined above however suggested that quiescent T cells might be a source of viral release. To this date, only a handful of studies have

examined the post integration events of the HIV life cycle in quiescent cells and in the absence of any stimulation. As quiescent T cells are transcriptionally less active and given the defects in the early stages of infection resulting in mutations of the viral cDNA as well as the potential integration into transcriptionally repressive regions, spontaneous viral release in HIV infected quiescent T cells can also be impaired. Recently studies using the SIV rhesus macaque model suggested that infected resting T cells can spontaneously release virions [47]. However, the transcriptional state of these cells was not fully examined. Our data as well as recent work have shown that multiply spliced *tat/rev* mRNA are lower in HIV infected quiescent and resting CD4 T cells [43,48-51]. This coupled with data from HIV patients on HAART that show elevated levels of unspliced viral mRNA compared to spliced would suggest that defects in splicing can impact the release of virions from quiescent T cells [48,52-54]. Furthermore, low levels of multiply spliced HIV RNA would result in lower levels of Tat protein as it has been shown to play a crucial role in transcriptional elongation [55-62] and recently in RNA splicing [63]. Such an outcome could have detrimental effects in the generation of higher levels of multiply spliced viral RNA. Yet, even if there is production of adequate levels of multiply spliced HIV RNA in quiescent T cells, this is further blocked by reduced nuclear export. This is due to the low levels of the polypyrimidine tract binding protein (PTB) in resting T cells. Low levels of PTB results in nuclear retention of multiply spliced viral RNA thus limiting the production of virions [49,51]. Despite these observed post-integration defects, recent work by Pace and colleagues demonstrated that there is observable but low Gag expression in HIV infected resting T cells [50]. However, this expression of Gag could not support a spreading infection, as the levels of Env protein were very low.

#### **Restriction factors**

While the above studies identified and further refined the stages of HIV life cycle impacted in quiescent T cells, they did not address the mechanisms behind the block. As quiescent T cells are characterized by low transcriptional and metabolic activity, it was reasonable to infer that the lack of cellular substrates or raw materials can have a detrimental effect on viral replication. While pretreatment of quiescent T cells with nucleosides improved reverse transcription in these cells, it failed to rescue infection [64,65]. This suggested that the presence of inhibitory factors or the absence of other supportive processes were responsible for this phenotype.

A number of restriction factors against HIV-1 have been identified over the years such as APOBEC3G [66-80], TRIM5 [81-94], tetherin [95-105], MOV10 [106-109] and



recently micro RNAs [110-114]. However, the focus of this review will be on the restriction factors uniquely identified in quiescent CD4<sup>+</sup> T cells that may be responsible for the observed block to HIV-1 infection (Figure 1).

a. Murr1

Murr1 is involved in copper regulation and inhibits NFκB activity. This inhibition is mediated by blocking proteosomal degradation of IκB resulting in decreased NFκB activity [115]. Studies by Ganesh and colleagues found that the protein is highly expressed in T cells [115]. This in conjunction with the role of NFκB in HIV expression made this a strong candidate for a host restriction factor. Through siRNA-mediated knockdown, the authors demonstrated that downregulation of Murr1 resulted in increased Gag expression suggesting the Murr1 may regulate HIV infection in quiescent CD4<sup>+</sup> T cells. However, the method of siRNA delivery, nucleofection, even though it did not perturb the activation state of quiescent cells (based on T cell activation marker expression CD25, CD69 and HLA-DR), it may have facilitated infection. While these studies were quite interesting, there was no follow-up work performed to further elucidate the role of this protein.


b. JNK and Pin1

Recent studies highlighted the lack of a cellular protein rather than the presence of a restriction

factor as a potential block to HIV infection in quiescent T cells. More specifically, c-Jun N-terminal kinase (JNK) phosphorylates viral integrase, which in turn interacts with the peptidyl prolyl-isomerase enzyme Pin1 causing a conformational change in integrase [116]. This combined effect increases the stability of integrase allowing for viral integration to occur. In these studies quiescent T cells were found not to express JNK, thus ameliorating the role of Pin1 in facilitating HIV integration [116]. These results lend support to earlier studies demonstrating the presence of preintegrated viral cDNA in resting cells that can act as an inducible reservoir [27,30]. However, these studies did not address the major defects identified by us and others in the early stages of the HIV life cycle as well as the fact that the efficiency of HIV integration in quiescent cells is similar to that of activated cells [39,43,45,46].

c. Glut1

Glut1 has recently been implicated as a potential cellular factor that could facilitate HIV infection. Like JNK and Pin1, the absence of this protein seems to impact HIV infection [117]. Interestingly, its role is linked to the metabolic processes of T cells. More specifically, Glut1 is a major glucose transporter found in both mature T cells and thymocytes [117]. Protein expression is upregulated by IL-7 treatment or conventional T cell activation.



When Glut expression was knockdown in activated T cells, it resulted in decreased HIV infection of these cells [117]. Expression levels of the protein were further correlated with permissiveness to HIV infection as double positive thymocytes expressing high levels of Glut1 were more likely to be infected by HIV than their low expressing counterparts [117]. This study is quite intriguing as it is the first one linking cell metabolism to HIV replication.

d. Cytoskeleton

The cytoskeleton has been shown to have a key role in HIV replication [118]. The cell structure plays a key role in cell shape, motility, organelle organization and intracellular trafficking [118]. This section involves multiple factors that have been recently identified to facilitate or block HIV infection. Early work showed that the HIV reverse transcription complex interacted with actin and disruption of the interaction resulted in blocking infection [119]. These studies suggested that the cytoskeleton was crucial for a productive HIV infection. Subsequent studies explored the molecular mechanisms of this phenomenon. More specifically, Yoder and colleagues showed that cross linking of CXCR4, one of the co-receptors for the virus, results in activation of cofilin, an actin that allows for HIV to rearrange actin and, consequently, facilitate infection [120]. This was further supported by patient studies showing that resting T cells isolated from HIV infected individuals had elevated levels of active cofilin thus facilitating the spread of infection [121]. In addition to CXCR4, crosslinking of CCR7, CXCR3, and CCR6 have been shown to activate cofilin and mediate the establishment of a latent HIV infection in resting T cells [122]. However, cofilin is not the sole factor involved in the interplay between HIV and actin. LIM domain kinase 1 (LIMK1), which phosphorylates cofilin and inactivates it, becomes activated following cross-linking of gp120 and CXCR4 [123]. This leads to actin polymerization and stabilization of the CD4/CXCR4 cluster allowing for efficient viral entry and uncoating. The stable complex then activates cofilin to further facilitate infection. This pathway was recently shown to be disrupted by the N-terminal fragment of Slit2 a secreted glycoprotein and reversed the HIV mediated changes in actin thus inhibiting infection [124]. These studies underscore the importance of cytoskeleton in HIV infection and have become an exciting area of HIV research as they can lead to the development of new therapies against the virus.

e. SAMDH1

The Sterile Alpha Motif (SAM) domain and HD domain-containing protein 1 (SAMHD1) has been

recently identified as a potential restriction factor in quiescent T cells. SAMHD1, like APOBEC3G, seems to target the early stages of the HIV life cycle more specifically reverse transcription. SAMHD1 is mutated in a subset of patients suffering from the Aicardi-Goutieres syndrome (AGS), an early-onset encephalopathy that mimics a congenital infection and is associated with increased levels of IFN- $\alpha$ ; production [125]. Studies suggested that the protein may be involved in negatively regulating innate immune responses [125]. With regards to HIV restriction, studies showed that SAMHD1 mediated the restriction to HIV infection in dendritic cells and monocytes [126-128]. The observed restriction of SAMHD1 was alleviated by the lentiviral protein Vpx, which is expressed in SIV [127,129]. When Vpx, a relative of Vpr the viral accessory protein expressed in HIV-1, was introduced into macrophages and monocyte derived dendritic cells, it significantly enhanced their infection by HIV [130-132]. Additional studies revealed that SAMHD1 is a strong dGTP triphosphohydrolase, thus impacting total nucleotide pools in cells [133,134]. By depleting these pools SAMHD1 inhibits reverse transcription thus restricting HIV replication [135].

While a number of studies employed gene knockdown to further elucidate the role of SAMHD1 and other restriction factors in HIV infection, the use of cell samples from AGS patients has proven particularly beneficial as it eliminated the variable of cell manipulation. Monocytes and dendritic cells from AGS patients were susceptible to HIV infection [127,128]. With respect to quiescent T cells, two studies have independently shown that the protein is abundantly expressed in them [136,137]. Both the SAMDH1 depleted and AGS patient derived CD4 T cells demonstrated improved HIV infection due to increased reverse transcription [136,137]. However, the expression of viral progeny was still defective in quiescent cells as suggested by both studies. In addition, even though SAMHD1 is also highly expressed in activated T cells, its inhibitory effects are only seen in quiescent T cells [127,135,136]. Thus, the combination of both limiting endogenous pools of nucleotides in quiescent T cells and the presence of SAMHD1 have a combined inhibitory effect on viral replication. As the field further explores the role of SAMHD1 it is clear that the protein limits the available nucleotide pools in quiescent cells thus restricting efficient reverse transcription. However, as previous studies have shown, a mere addition of nucleosides while improving reverse transcription does not remedy the block seen in quiescent T cells [64,65].

## Conclusions

In conclusion, the mechanisms and/or cellular factors mediating the block in the HIV infection of quiescent CD4 T cell are not fully understood yet. While a number of cellular factors have been implicated, it is clear that the blocking effect to HIV infection is mediated by multiple events due to the physiology of quiescent T cells. Cellular size, transcriptional and metabolic activities are all important cell functions that are used by intracellular parasites such as viruses to successfully infect and replicate into the host cells.

Based on the early and subsequent work, the characterization of the HIV life cycle in quiescent T cells strongly indicate that the major impact to infection occurs very early, immediately following viral entry at the initiation of reverse transcription. While limited raw materials such as nucleotides impacted by both the nature of quiescent cells and SAMHD1 can result in decreased levels of reverse transcription, it is clear that downstream events prior to integration or even at integration are quite important. In addition, another process that is widely bypassed due to technical challenges, uncoating can be impacted in quiescent cells and be detrimental to infection [138,139].

Therefore, further studies are needed to understand the block in quiescent T cells. To this date, based on what we know and the nature of cellular factors identified, it is not clear how the mechanisms of resistance in quiescent cells can translate into future therapies. Nevertheless, these studies will allow us to better understand the relationship between HIV and its various target cells which can ultimately lead to more effective interventions.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JAZ, SGK and DNV wrote and edited the manuscript; SGK prepared the manuscript figure. All authors read and approved the final manuscript.

## Acknowledgements

This work was supported by NIH grants R21DA031036-01A1 (DNV), 5P30 AI028697 (UCLA/CFAR, JAZ), R01AI070010, (J.A.Z.).

## Author details

<sup>1</sup>Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. <sup>2</sup>Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. <sup>3</sup>UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Received: 12 February 2013 Accepted: 1 April 2013

Published: 4 April 2013

## References

1. Yusuf I, Fruman DA: Regulation of quiescence in lymphocytes. *Trends Immunol* 2003, **24**:380–386.
2. Tzachanis D, Lafuente EM, Li L, Boussiotis VA: Intrinsic and extrinsic regulation of T lymphocyte quiescence. *Leuk Lymphoma* 2004, **45**:1959–1967.
3. Kuo CT, Veselits ML, Leiden JM: LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. *Science* 1997, **277**:1986–1990.
4. Buckley AF, Kuo CT, Leiden JM: Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. *Nat Immunol* 2001, **2**:698–704.
5. Di Santo JP: Lung Kruppel-like factor: a quintessential player in T cell quiescence. *Nat Immunol* 2001, **2**:667–668.
6. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA: Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. *Nat Immunol* 2001, **2**:1174–1182.
7. Coffey PJ: Transcriptional regulation of lymphocyte quiescence: as cunning as a FOX. *Trends Immunol* 2003, **24**:470–471. author reply 471.
8. Haaland RE, Yu W, Rice AP: Identification of LKLF-regulated genes in quiescent CD4+ T lymphocytes. *Mol Immunol* 2005, **42**:627–641.
9. Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang WW, Kaestner KH, Fruman DA: KLF4 is a FOXO target gene that suppresses B cell proliferation. *Int Immunol* 2008, **20**:671–681.
10. Tzachanis D, Boussiotis VA: Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. *Cell Cycle* 2009, **8**:1019–1025.
11. Burgering BM, Kops GJ: Cell cycle and death control: long live Forkheads. *Trends Biochem Sci* 2002, **27**:352–360.
12. Burgering BM: A brief introduction to FOXology. *Oncogene* 2008, **27**:2258–2262.
13. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 2000, **404**:782–787.
14. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, Huang TT, Bos JL, Medema RH, Burgering BM: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 2002, **419**:316–321.
15. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompaker R, Kops GJ, Lam EW, Burgering BM, Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. *Mol Cell Biol* 2002, **22**:7842–7852.
16. Fabre S, Lang V, Harriague J, Jobart A, Unterman TG, Trautmann A, Bismuth G: Stable activation of phosphatidylinositol 3-kinase in the T cell immunological synapse stimulates Akt signaling to FoxO1 nuclear exclusion and cell growth control. *J Immunol* 2005, **174**:4161–4171.
17. Peng SL: Foxo in the immune system. *Oncogene* 2008, **27**:2337–2344.
18. Ouyang W, Beckett O, Flavell RA, Li MO: An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. *Immunity* 2009, **30**:358–371.
19. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, Yoshida M, Emi M, Nakamura Y, Onda M, Yoshida Y, Nishiyama A, Yamamoto T: Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. *Oncogene* 1996, **12**:705–713.
20. Jia S, Meng A: Tob genes in development and homeostasis. *Dev Dyn* 2007, **236**:913–921.
21. Stevenson M: HIV-1 pathogenesis. *Nat Med* 2003, **9**:853–860.
22. Weinberg JB, Matthews TJ, Cullen BR, Malim MH: Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. *J Exp Med* 1991, **174**:1477–1482.
23. Lewis P, Hensel M, Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle. *Embo J* 1992, **11**:3053–3058.
24. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppeler-Campbell JA, Hicks D, Sligh J: Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. *J Immunol* 1985, **135**:3151–3162.
25. Zagury D, Bernard J, Leonard R, Cheyner R, Feldman M, Sarin PS, Gallo RC: Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. *Science* 1986, **231**:850–853.
26. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG: Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. *J Immunol* 1989, **142**:773–780.
27. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. *Embo J* 1990, **9**:1551–1560.
28. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. *Cell* 1990, **61**:213–222.



29. Zack JA, Haislip AM, Krogstad P, Chen IS: Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. *J Virol* 1992, **66**:1717–1725.
30. Spina CA, Guatelli JC, Richman DD: Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. *J Virol* 1995, **69**:2977–2988.
31. Ramilo O, Bell KD, Uhr JW, Vitetta ES: Role of CD25+ and CD25- T cells in acute HIV infection in vitro. *Journal of Immunology* 1993, **150**:5202–5208.
32. Borvak J, Chou CS, Bell K, Van Dyke G, Zola H, Ramilo O, Vitetta ES: Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. *Journal of Immunology* 1995, **155**:3196–3204.
33. Chou CS, Ramilo O, Vitetta ES: Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. *Proceedings of the National Academy of Sciences of the United States of America* 1997, **94**:1361–1365.
34. Tang S, Patterson B, Levy JA: Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. *J Virol* 1995, **69**:5659–5665.
35. Korin YD, Zack JA: Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. *J Virol* 1998, **72**:3161–3168.
36. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF: Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. *J Virol* 2002, **76**:8518–8531.
37. Zhou Y, Zhang H, Siliciano JD, Siliciano RF: Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. *J Virol* 2005, **79**:2199–2210.
38. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH: A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. *J Virol* 2002, **76**:10942–10950.
39. Swiggard WJ, O'Doherty U, McGain D, Jeyakumar D, Malim MH: Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. *AIDS Res Hum Retroviruses* 2004, **20**:285–295.
40. Swiggard WJ, Baytop C, Yu JJ, Dai J, Li C, Schretzenmair R, Theodosopoulos T, O'Doherty U: Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. *J Virol* 2005, **79**:14179–14188.
41. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O'Doherty U: HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. *Virology* 2007, **368**:60–72.
42. O'Doherty U, Swiggard WJ, Malim MH: Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. *J Virol* 2000, **74**:10074–10080.
43. Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA: Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. *J Virol* 2007, **81**:3574–3582.
44. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC, Margolick JB, Siliciano JD, Siliciano RF: Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. *J Virol* 2004, **78**:6122–6133.
45. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA: HIV integration efficiency and site selection in quiescent CD4+ T cells. *J Virol* 2009, **10**:1128. JVI.00356-09.
46. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, Bushman F: HIV integration site distributions in resting and activated CD4+ T cells infected in culture. *AIDS* 2009, **23**:1461–1471.
47. Nishimura Y, Sadjadpour R, Mattapallil JJ, Igarashi T, Lee W, Buckler-White A, Roederer M, Chun TW, Martin MA: High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. *Proc Natl Acad Sci U S A* 2009, **106**:8015–8020.
48. Lassen KG, Bailey JR, Siliciano RF: Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. *J Virol* 2004, **78**:9105–9114.
49. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF: Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. *PLoS Pathog* 2006, **2**:e68.
50. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U: Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. *PLoS Pathog* 2012, **8**:e1002818.
51. Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR: Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. *Retrovirology* 2011, **8**:80.
52. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Gunthard HF: Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. *Retrovirology* 2008, **5**:107.
53. Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, Trkola A, Kuster H, Weber R, Gunthard HF, Swiss HIVCS: Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. *Antivir Ther* 2002, **7**:91–103.
54. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov W: Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. *PLoS ONE* 2009, **4**:e8490.
55. Sobhian B, Laguetta N, Yatim A, Nakamura M, Levy Y, Kiernan R, Benkirane M: HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 75K snRNP. *Molecular cell* 2010, **38**:439–451.
56. Zhou Q, Sharp PA: Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. *Science* 1996, **274**:605–610.
57. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, et al: Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. *Embo J* 2007, **26**:424–435.
58. Marciniak RA, Sharp PA: HIV-1 Tat protein promotes formation of more-processive elongation complexes. *Embo J* 1991, **10**:4189–4196.
59. Parada CA, Roeder RG: A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. *Embo J* 1999, **18**:3688–3701.
60. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* 1998, **92**:451–462.
61. Feinberg M, Baltimore D, Frankel A: The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. *PNAS* 1991, **88**:4045–4049.
62. Selby MJ, Peterlin BM: Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. *Cell* 1990, **62**:769–776.
63. Jablonski JA, Amelio AL, Giacca M, Caputi M: The transcriptional transactivator Tat selectively regulates viral splicing. *Nucleic Acids Res* 2010, **38**:1249–1260.
64. Korin YD, Zack JA: Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. *J Virol* 1999, **73**:6526–6532.
65. Plesa G, Dai J, Baytop C, Riley JL, June CH, O'Doherty U: Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. *J Virol* 2007, **81**:13938–13942.
66. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. *Nat Med* 1998, **4**:1397–1400.
67. Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH: The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. *Embo J* 1998, **17**:1259–1267.
68. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* 2002, **418**:646–650.
69. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. *Curr Biol* 2003, **13**:2009–2013.
70. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. *Cell* 2003, **113**:803–809.
71. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature* 2003, **424**:99–103.
72. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. *Cell* 2003, **114**:21–31.

73. Marin M, Rose KM, Kozak SL, Kabat D: **HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.** *Nat Med* 2003, **9**:1398–1403.
74. Sheehy AM, Gaddis NC, Malim MH: **The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.** *Nat Med* 2003, **9**:1404–1407.
75. Stopak K, de Noronha C, Yonemoto W, Greene WC: **HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.** *Mol Cell* 2003, **12**:591–601.
76. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: **Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.** *Science* 2003, **302**:1056–1060.
77. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: **The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.** *Nature* 2003, **424**:94–98.
78. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC: **Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.** *Nature* 2005, **435**:108–114.
79. Kamata M, Nagaoka Y, Chen IS: **Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.** *PLoS Pathog* 2009, **5**:e1000342.
80. de Sio FR S, Trono D: **APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection.** *PLoS ONE* 2009, **4**:e6571.
81. Besnier C, Takeuchi Y, Towers G: **Restriction of lentivirus in monkeys.** *Proc Natl Acad Sci USA* 2002, **99**:11920–11925.
82. Cowan S, Hatzioannou T, Cunningham T, Muesing M, Gottlinger H, Bieniasz P: **Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism.** *Proc Natl Acad Sci USA* 2002, **99**:11914–11919.
83. Hatzioannou T, Cowan S, Goff S, Bieniasz P, Towers G: **Restriction of multiple divergent retroviruses by Lv1 and Ref1.** *EMBO J* 2003, **22**:385–394.
84. Kono K, Song H, Yokoyama M, Sato H, Shioda T, Nakayama E: **Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5alpha-mediated restriction.** *Retrovirology* 2010, **7**:72.
85. Kuroishi A, Bozek K, Shioda T, Nakayama E: **A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5alpha.** *Retrovirology* 2010, **7**:58.
86. Langelier C, Sandrin V, Eckert D, Christensen D, Chandrasekaran V, Alam S, Aiken C, Olsen J, Kar A, Sodroski J: **Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication.** *J Virol* 2008, **82**:11682–11694.
87. Lee K, KewalRamani V: **In defense of the cell: TRIM5alpha interception of mammalian retroviruses.** *Proc Natl Acad Sci USA* 2004, **101**:10496–10497.
88. Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, Diaz-Griffero F: **Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5alpha(rh): structure of the RING domain of TRIM5alpha.** *J Virol* 2011, **85**:8725–8737.
89. Lukic Z, Hausmann S, Sebastian S, Rucci J, Sastri J, Robia S, Luban J, Campbell E: **TRIM5alpha associates with proteasomal subunits in cells while in complex with HIV-1 virions.** *Retrovirology* 2011, **8**:93.
90. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C: **RING domain mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.** *J Virol* 2012, **86**:1717–1727.
91. Sayah D, Sokolskaja E, Berthoux L, Luban J: **Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.** *Nature* 2004, **430**:569–573.
92. Stremlau M, Owens C, Perron M, Kiessling M, Autissier P, Sodroski J: **The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.** *Nature* 2004, **427**:848–853.
93. Towers G, Bock M, Martin S, Takeuchi Y, Stoye J, Danos O: **A conserved mechanism of retrovirus restriction in mammals.** *Proc Natl Acad Sci USA* 2000, **97**:12295–12299.
94. Wu X, Anderson J, Campbell E, Joseph A, Hope T: **Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.** *Proc Natl Acad Sci USA* 2006, **103**:7465–7470.
95. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin A-G, Guatelli J, Schwartz O: **Tetherin restricts productive HIV-1 cell-to-cell transmission.** *PLoS Pathog* 2010, **6**:e1000955.
96. Chu H, Wang J, Qi M, Yoon J, Chen X, Wen X, Hammonds J, Ding L, Spearman P: **Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages.** *Cell Host Microbe* 2012, **12**:360–372.
97. Fitzpatrick K, Skasko M, Deerinck T, Crum J, Ellisman M, Guatelli J: **Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.** *PLoS Pathog* 2010, **6**:e1000701.
98. Jolly C, Booth N, Neil S: **Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.** *J Virol* 2010, **84**:12185–12199.
99. Kuhl B, Sloan R, Donahue D, Bar-Magen T, Liang C, Wainberg M: **Tetherin restricts direct cell-to-cell infection of HIV-1.** *Retrovirology* 2010, **7**:115.
100. Liberatore R, Bieniasz P: **Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo.** *Proc Natl Acad Sci USA* 2011, **108**:18097–18101.
101. Neil S, Eastman S, Jouvenet N, Bieniasz P: **HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.** *PLoS Pathog* 2006, **2**:e39.
102. Neil S, Sandrin V, Sundquist W, Bieniasz P: **An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.** *Cell Host Microbe* 2007, **2**:193–203.
103. Neil S, Zang T, Bieniasz P: **Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.** *Nature* 2008, **451**:425–430.
104. Van Damme N, Goff D, Katsura C, Jorgenson R, Mitchell R, Johnson M, Stephens E, Guatelli J: **The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.** *Cell Host Microbe* 2008, **3**:245–252.
105. Varthakavi V, Smith R, Bour S, Strebel K, Spearman P: **Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.** *Proc Natl Acad Sci USA* 2003, **100**:15154–15159.
106. Arjan-Odedra S, Swanson C, Sherer N, Wolinsky S, Malim M: **Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses.** *Retrovirology* 2012, **9**:53.
107. Burdick R, Smith J, Chaipan C, Friew Y, Chen J, Venkatachari N, Delviks-Frankenberry K, Hu W, Pathak V: **P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages.** *J Virol* 2010, **84**:10241–10253.
108. Furtak V, Mulky A, Rawlings S, Kozhaya L, Lee K, Kewalramani V, Unutmaz D: **Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity.** *PLoS One* 2010, **5**:e9081.
109. Wang X, Han Y, Dang Y, Fu W, Zhou T, Ptak R, Zheng Y: **Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication.** *J Biol Chem* 2010, **285**:14346–14355.
110. Ahluwalia J, Khan S, Soni K, Rawat P, Gupta A, Hariharan M, Scaria V, Lalwani M, Pillai B, Mitra D: **Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication.** *Retrovirology* 2008, **5**:117.
111. Althaus C, Vongrad V, Niederost B, Joos B, Di Giallonardo F, Rieder P, Pavlovic J, Trkola A, Gunthard H, Metzner K: **Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells.** *Retrovirology* 2012, **9**:27.
112. Kobayashi-Ishihara M, Yamagishi M, Hara T, Matsuda Y, Takahashi R, Miyake A, Nakano K, Yamochi T, Ishida T, Watanabe T: **HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period.** *Retrovirology* 2012, **9**:38.
113. Schopman N, Willemsen M, Liu Y, Bradley T, van Kampen A, Baas F, Berkhout B, Haasnoot J: **Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs.** *Nucleic Acids Res* 2012, **40**:414–427.
114. Yeung M, Bennasser Y, Watashi K, Le S, Houzet L, Jeang K: **Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid.** *Nucleic Acids Res* 2009, **37**:6575–6586.
115. Ganesh L, Burstein E, Guha-Niyogi A, Louder MK, Mascola JR, Klomp LW, Wijemanga C, Duckett CS, Nabel GJ: **The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.** *Nature* 2003, **426**:853–857.
116. Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M: **Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes.** *Nat Med* 2010, **16**:329–333.
117. Loisel-Meyer S, Swainson L, Craveiro M, Oburoglu L, Mongellaz C, Costa C, Martinez M, Cosset FL, Battini JL, Herzenberg LA, et al: **Glut1-mediated glucose transport regulates HIV infection.** *Proc Natl Acad Sci U S A* 2012, **109**:2549–2554.



118. Matarrese P, Malorni W: **Human immunodeficiency virus (HIV)-1 proteins and cytoskeleton: partners in viral life and host cell death.** *Cell Death Differ* 2005, **12**(Suppl 1):932–941.
119. Bukrinskaya A, Brichacek B, Mann A, Stevenson M: **Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton.** *J Exp Med* 1998, **188**:2113–2125.
120. Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, et al: **HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells.** *Cell* 2008, **134**:782–792.
121. Wu Y, Yoder A, Yu D, Wang W, Liu J, Barrett T, Wheeler D, Schlauch K: **Cofilin activation in peripheral CD4 T cells of HIV-1 infected patients: a pilot study.** *Retrovirology* 2008, **5**:95.
122. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, Boucher G, Haddad EK, Sekaly RP, Harman AN, et al: **Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.** *Proc Natl Acad Sci U S A* 2010, **107**:16934–16939.
123. Vorster PJ, Guo J, Yoder A, Wang W, Zheng Y, Xu X, Yu D, Spear M, Wu Y: **LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection.** *J Biol Chem* 2011, **286**:12554–12564.
124. Anand AR, Zhao H, Nagaraja T, Robinson LA, Ganju RK: **N-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton.** *Retrovirology* 2013, **10**:2.
125. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, et al: **Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response.** *Nat Genet* 2009, **41**:829–832.
126. St Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, Kim B, Wu L: **SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons.** *Retrovirology* 2012, **9**:105.
127. Laguette N, Sobhian B, Casartelli N, Ringiard M, Chable-Bessia C, Segéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M: **SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.** *Nature* 2011, **474**:654–657.
128. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, et al: **SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection.** *PLoS Pathog* 2011, **7**:e1002425.
129. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J: **Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.** *Nature* 2011, **474**:658–661.
130. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M: **A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection.** *Cell Host Microbe* 2009, **6**:68–80.
131. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, Stevenson M: **Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction.** *PLoS Pathog* 2008, **4**:e1000057.
132. Ayinde D, Maudet C, Transy C, Margottin-Goguet F: **Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?** *Retrovirology* 2010, **7**:35.
133. Powell RD, Holland PJ, Hollis T, Perrino FW: **Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase.** *J Biol Chem* 2011, **286**:43596–43600.
134. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, et al: **HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase.** *Nature* 2011, **480**:379–382.
135. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, et al: **SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.** *Nat Immunol* 2012, **13**:223–228.
136. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M: **SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells.** *Retrovirology* 2012, **9**:87.
137. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, et al: **SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.** *Nat Med* 2012, **18**:1682–1687.
138. Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S, Puthavathana P: **Uncoating of HIV-1 requires cellular activation.** *Virology* 2005, **337**:93–101.
139. Arhel N: **Revisiting HIV-1 uncoating.** *Retrovirology* 2010, **7**:96.

doi:10.1186/1742-4690-10-37

Cite this article as: Zack et al: HIV restriction in quiescent CD4+ T cells. *Retrovirology* 2013 **10**:37.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

